Blue test tubes arranged in a line, disappearing into the background

Drug news

Valeant Pharmaceuticals and Progenics announce the US launch of Relistor (methylnaltrexone bromide) Tablets to treat opioid-induced constipation in adults with chronic non-cancer pain .

Read time: 1 mins

Last updated:7th Sep 2016

Published:7th Sep 2016

Source: Pharmawand

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc.announced the U.S. commercial launch of Relistor (methylnaltrexone bromide) Tablets, which is now available for prescribing. Relistor Tablets (450 mg once daily) were approved by the FDA for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

Results from the Phase III ARANOTE trial have shown that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with metastatic hormone-sensitive prostate cancer (mHSPC)

4 mins

Drug news

Ten-year data for Keytruda (pembrolizumab) demonstrates sustained overall survival benefit versus ipilimumab in advanced melanoma

Merck ( known as MSD outside of the United States and Canada ) announced long-term overall survival (OS) data from the pivotal Phase III KEYNOTE-006 trial, evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma

2 min

Drug news

FDA approval of dupixent (dupilumab) to treat rhinosinusitis with nasal polyps

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

1 min

See all news